Prezzo di chiusura
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
903,6 USD | 0,00% | 0,00% | 0,00% |
05/07 | L'ETF della settimana: investire in trend forti con il tema del momentum | |
03/07 | Azioni da tenere d'occhio mentre Biden e Trump si sfidano per la presidenza | RE |
Attività
- endocrinologia (57,7%): prodotti per il trattamento dell'osteoporosi, del diabete e dei problemi di crescita;
- oncologia (19,5%);
- malattie immunologiche (11,1%);
- neurologia (8,4%): principalmente farmaci utilizzati nel trattamento della depressione e della schizofrenia;
- altro (3,3%).
Le vendite nette sono distribuite geograficamente come segue: Stati Uniti (63,9%), Europa (18,1%), Giappone (4,9%), Cina (4,5%) e altro (8,6%).
Numero di dipendenti: 43 000
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Human Pharmaceutical Products
100,0
%
| 28 541 | 100,0 % | 34 124 | 100,0 % | +19,56% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
63,9
%
| 18 190 | 63,7 % | 21 791 | 63,9 % | +19,80% |
Europe
18,1
%
| 4 299 | 15,1 % | 6 175 | 18,1 % | +43,62% |
Other Foreign Countries
8,6
%
| 2 852 | 10,0 % | 2 946 | 8,6 % | +3,30% |
Japan
4,9
%
| 1 747 | 6,1 % | 1 673 | 4,9 % | -4,28% |
China
4,5
%
| 1 453 | 5,1 % | 1 540 | 4,5 % | +5,98% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01/01/96 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 16/10/23 |
Alonzo Weems
CMP | Compliance Officer | - | 01/01/97 |
Chief Tech/Sci/R&D Officer | 50 | 01/01/18 | |
Diogo Rau
CTO | Chief Tech/Sci/R&D Officer | - | 17/05/21 |
Johna Norton
PRN | Corporate Officer/Principal | 57 | 01/04/17 |
Corporate Officer/Principal | - | 01/01/05 | |
Ilya Yuffa
PRN | Corporate Officer/Principal | 49 | - |
- | - |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Director/Board Member | 63 | 25/01/21 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01/04/09 |
Jon Fyrwald
BRD | Director/Board Member | 64 | 01/01/05 |
Juan Luciano
BRD | Director/Board Member | 62 | 01/02/16 |
William Kaelin
BRD | Director/Board Member | 66 | 04/06/12 |
David Ricks
CEO | Chief Executive Officer | 56 | 01/01/96 |
Jamere Jackson
BRD | Director/Board Member | 54 | 01/10/16 |
Director/Board Member | 52 | 12/12/11 | |
Marschall Runge
BRD | Director/Board Member | 69 | 01/09/13 |
Karen Walker
BRD | Director/Board Member | 62 | 01/12/18 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 950 770 386 | 948 828 530 ( 99,80 %) | 365 000 ( 0,0384 %) | 99,80 % |
Partecipazioni
Nome | Azioni | % | Valorizzazione |
---|---|---|---|
IMMUNOCORE HOLDINGS PLC 6.25% | 2 548 145 | 6.25% | 124 808 142 $ |
8 084 411 | 6.83% | 44 026 813 $ | |
PROQR THERAPEUTICS N.V. 16.37% | 13 371 562 | 16.37% | 26 074 546 $ |
4 000 000 | 7.23% | 23 320 000 $ | |
AC IMMUNE SA 3.64% | 3 615 328 | 3.64% | 16 811 275 $ |
21 776 804 | 7.60% | 10 995 108 $ | |
125 405 | 1.81% | 1 617 725 $ |
Coordinate società
Società del gruppo
Nome | Categoria e settore |
---|---|
ELI Lilly & Company (India) Pvt Ltd.
ELI Lilly & Company (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology ELI Lilly & Company (India) Pvt Ltd. manufactures and markets pharmaceutical products. The firm's products treat diabetes, gastric cancer, lung cancer, osteoporosis, rheumatoid arthritis, men's health and growth-hormone deficiency. The company was founded in 1993 and is headquartered in Gurgaon, India. |
Pharmaceuticals: Major
|
Eli Lilly Services India Pvt Ltd.
Eli Lilly Services India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Services India Pvt Ltd. is an Indian company that discovers, develops, manufactures and sells pharmaceutical products. The company is based in Bangalore, India and was founded in 2015. |
Pharmaceuticals: Major
|
Eli Lilly Export SA (Switzerland)
Eli Lilly Export SA (Switzerland) Medical DistributorsDistribution Services Part of Eli Lilly & Co., Eli Lilly Export SA is a pharmaceutical company based in Vernier, Switzerland. The Swiss company combines care with research to develop innovative solutions for a better life worldwide. |
Medical Distributors
|
Kinsale Financial Services
| |
Lilly Nederland Finance BV
Lilly Nederland Finance BV Miscellaneous Commercial ServicesCommercial Services Part of Eli Lilly & Co., Lilly Nederland Finance BV leases non-financial intangible assets. The company is based in Utrecht, Netherlands. |
Miscellaneous Commercial Services
|
Eli Lilly SA
Eli Lilly SA Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly SA is a Swiss company that manufactures medicines. The company is based in Vernier, Switzerland. |
Pharmaceuticals: Major
|
Eli Lilly (Suisse) SA
| |
Lilly Global Nederland Holdings BV
Lilly Global Nederland Holdings BV Financial ConglomeratesFinance Part of Eli Lilly & Co., Lilly Global Nederland Holdings BV functions as an investment holding Dutch company. The company is based in Utrecht, Netherlands. |
Financial Conglomerates
|
Eli Lilly Vostok SA
|
Settore
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+39,52% | 624 Mrd | |
-6,55% | 351 Mrd | |
+7,92% | 289 Mrd | |
+13,74% | 240 Mrd | |
+13,83% | 220 Mrd | |
-0,49% | 219 Mrd | |
+7,94% | 166 Mrd | |
-2,57% | 157 Mrd | |
+1,31% | 123 Mrd |
- Borsa valori
- Azioni
- Azione LLY
- Azione
- Società Eli Lilly and Company